Sarepta Therapeutics | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (62)

View All

Latest Posts

About This Stock More About This Stock
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
Article By: Zacks Investment Research
Sunday, January 7, 2024 9:00 AM EDT
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech stocks that will likely perform well in 2024.
In this article: REGN, SRPT, BGNE
Read
New Sarepta DMD Data Leads To Old Debates
Article By: Bio Deep Dives
Monday, October 30, 2023 10:26 PM EDT
Sarepta released their Phase III EMBARK data that is actually consistent with my previous analysis that the drug likely works in younger patients but not older. EMBARKNG On A New Label?
In this article: SRPT
Read
Sarepta: The AdCom Documents Enter The Discussion
Article By: Bio Deep Dives
Wednesday, May 10, 2023 2:00 PM EDT
The AdCom documents are going to stimulate a robust discussion about the upcoming vote.
In this article: SRPT
Read
Sarepta: More Drama Or Just More Noise?
Article By: Bio Deep Dives
Friday, April 14, 2023 2:35 PM EDT
Sarepta has a history at the FDA and recent reports indicate additional issues. What are the implications for accelerated approval and the long term prospects of Sarepta?
In this article: SRPT
Read
5 Gene Therapy Stocks Back In Focus On AbbVie/Regenxbio Deal
Article By: Zacks Investment Research
Tuesday, September 14, 2021 3:32 PM EDT
Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector.
In this article: SRPT, QURE, SLDB, MGTX, VYGR Also: ABBV, RGNX
Read
All Posts

Latest Tweets for $SRPT

No tweets yet!

PARTNER HEADLINES

$SRPT

Comments Status Updates
Why Sarepta Therapeutics Inc Looks On Track For A Second DMD Approval
Carol Klein • 10/11/2017 1:39:12 PM

Looks promising, thanks. $SRPT.

1 to 1 of 1 comments